Our site uses cookies to make navigation as functional as possible, including "third party" cookies and "profiling cookies" designed to tailor on-line contents to suit the preferences expressed while surfing the internet. Should you wish to receive more information, or deny your consent to some or all cookies, click here. If you proceed browsing this website, you will be consenting to the use of all cookies.

MEN1112

Monoclonal human antibody (ADCC)

ONCOLOGY

CURRENT DEVELOPMENT PHASE: AML / ACUTE MYELOID LEUKAEMIA

preclinicl
phase i
phase ii
phase iii
registration
post-registration

Acute myeloid leukaemia accounts for approximately 30% of blood cancers, with an incidence of 30,000 new cases in Europe per year (2,000 in Italy). It is a disease with a severe prognosis, with only 24% of patients surviving at 5 years.

MEN1112 is the first monoclonal antibody to be developed in the collaboration between Menarini and OBT (Oxford BioTherapeutics) that acts through an ADCC (Antibody-Dependent Cellular Toxicity) mechanism of action.




The target of MEN1112 is CD157, a protein expressed on leukemic cancer cells (blasts); data showing antitumor effects on cancer cell lines and on leukemic blasts from patients are now available.

The biotechnological process for the production of MEN1112 has been developed at Menarini Biotech in Pomezia. The first in human study in patients with relapsed/refractory acute myeloid leukemia (clinical study ARMY) is ongoing.

 

VISIT OUR CLINICAL TRIALS DATABASE


THERAPEUTIC AREAS

Discover all of Menarini's products marketed in Italy. Read More »

DIAGNOSTICS

 

Advanced Technology

READ MORE »

THE MENARINI GROUP

Discover the leading Italian pharmaceutical company in the world. Read More »

MENARINI PILLS OF ART

Concession granted by Italian Ministry for Cultural Heritage and Activities Read more